I'm absolutely not defending the high price of Solvadi, but that article is naive in the extreme, as the low figure given would (obviously) fail to:
1) Amortize the costs (~$1.1Bn) incurred in the development of the drug in question
2) Amortize the costs of the manufacturer's other development failures
